US sales Flat QoQ: We expect US sales to remain steady QoQ with continued challenging environment and lack of meaningful approvals. Sun Pharma's specialty sales are likely to increase in Q4FY22 as traction in WINLEVI product continues. Given lack of meaningful approvals and continued...